Summit Therapeutics (SMMT) Non-Current Receivables (2021 - 2024)
Historic Non-Current Receivables for Summit Therapeutics (SMMT) over the last 4 years, with Q4 2024 value amounting to $698000.0.
- Summit Therapeutics' Non-Current Receivables fell 2721.58% to $698000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $698000.0, marking a year-over-year decrease of 2721.58%. This contributed to the annual value of $698000.0 for FY2024, which is 2721.58% down from last year.
- Per Summit Therapeutics' latest filing, its Non-Current Receivables stood at $698000.0 for Q4 2024, which was down 2721.58% from $467000.0 recorded in Q3 2024.
- In the past 5 years, Summit Therapeutics' Non-Current Receivables registered a high of $11.3 million during Q3 2021, and its lowest value of $212000.0 during Q1 2024.
- For the 4-year period, Summit Therapeutics' Non-Current Receivables averaged around $2.4 million, with its median value being $747000.0 (2023).
- In the last 5 years, Summit Therapeutics' Non-Current Receivables crashed by 7791.65% in 2023 and then crashed by 2721.58% in 2024.
- Summit Therapeutics' Non-Current Receivables (Quarter) stood at $11.3 million in 2021, then tumbled by 70.82% to $3.3 million in 2022, then crashed by 70.95% to $959000.0 in 2023, then fell by 27.22% to $698000.0 in 2024.
- Its Non-Current Receivables was $698000.0 in Q4 2024, compared to $467000.0 in Q3 2024 and $364000.0 in Q2 2024.